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Abstract
Purpose In recent years there has been an increase in the
development of radioligands targeting the 18-kDa translocator
protein (TSPO). TSPO expression is well documented in acti-
vated microglia and serves as a biomarker for imaging neuro-
inflammation. In addition, TSPO has also been reported to be
overexpressed in a number of cancer cell lines and human
tumours including glioma. Here we investigated the use of
[18F]DPA-714, a new TSPO positron emission tomography
(PET) radioligand to image glioma in vivo.
Methods We studied the uptake of [18F]DPA-714 in three
different rat strains implanted with 9L rat glioma cells:
Fischer (F), Wistar (W) and Sprague Dawley (SD) rats.
Dynamic [18F]DPA-714 PET imaging, kinetic modelling
of PET data and in vivo displacement studies using unla-
belled DPA-714 and PK11195 were performed. Validation
of TSPO expression in 9L glioma cell lines and intracranial
9L gliomas were investigated using Western blotting and
immunohistochemistry of brain tissue sections.
Results All rats showed significant [18F]DPA-714 PET accu-
mulation at the site of 9L tumour implantation compared to the
contralateral brain hemisphere with a difference in uptake
among the three strains (F>W>SD). The radiotracer showed
high specificity for TSPO as demonstrated by the significant
reduction of [18F]DPA-714 binding in the tumour after admin-
istration of unlabelled DPA-714 or PK11195. TSPO expression
was confirmed by Western blotting in 9L cells in vitro and by
immunohistochemistry ex vivo.
Conclusion The TSPO radioligand [18F]DPA-714 can be
used for PET imaging of intracranial 9L glioma in different
rat strains. This preclinical study demonstrates the feasibility
of employing [18F]DPA-714 as an alternative radiotracer to
image human glioma.
Keywords Glioma . Translocator protein . TSPO .
Microglia . Positron emission tomography . Peripheral
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Introduction
The 18-kDa translocator protein (TSPO), also known as the
peripheral benzodiazepine receptor, is a protein of the outer
mitochondrial membrane expressed in peripheral organs and
is particularly enriched in steroidogenic tissue. In the central
nervous system (CNS) TSPO expression is low and limited
to resident glial cells [1].
However, cerebral TSPO expression is dramatically in-
creased after glial cell activation and has become a well-
characterized marker for neuroinflammation [2–6]. In addi-
tion, TSPO levels are also elevated in a number of cancer
cell lines and human tumours including breast, ovary, colon
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and prostate cancer, as well as glioma [7, 8]. Initial studies
on TSPO and TSPO ligands in the brain carried out in the
1980s and 1990s indicated that the density of TSPO was
high in malignant gliomas [9–12] and in glioma cell lines
[9–14]. Further studies demonstrated that TSPO expression
levels positively correlated with the grade of malignancy
and showed a negative correlation between TSPO expression
and survival [15, 16]. In the late 1980s positron emission
tomography (PET) imaging of human gliomas using TSPO
radioligands was suggested [11–13] and first demonstrated
with the isoquinoline derivative [11C]PK11195 [10, 17].
However, numerous limitations of this radioligand have been
reported, including the high level of non-specific binding and
the relatively poor signal-to-noise ratio [2].
In the last few years many efforts have been undertaken
in the development of new radioligands targeting the TSPO.
Thus, recently developed radioligands with improved in
vivo specificity for TSPO may have the potential to improve
PET imaging of TSPO expression in human gliomas. One of
the promising new radioligands for TSPO imaging is the
pyrazolo[1,5]pyrimidine [18F]DPA-714. [18F]DPA-714
demonstrated lower non-specific uptake and higher binding
potential (BP) as compared to [11C]PK11195 in a rat model
of acute neuroinflammation [18]. The aim of the present
study was to investigate the potential use of [18F]DPA-714
as a new PET imaging marker for glioma. Here we report
the use of [18F]DPA-714 to monitor TSPO-expressing
gliomas in vivo using PET imaging. The specificity of the
radioligand binding was confirmed by displacement studies
and the level of TSPO expression was assessed using
immunohistochemical analysis in syngeneic and allogeneic
9L rat glioma models.
Materials and methods
Radiochemicals and chemicals
Ready-to-inject, >99% radiochemically pure L-[11C]methio-
nine ([11C]MET, (S)-2-amino-4-([11C]methylsulfanyl)-buta-
noic acid) was prepared from cyclotron-produced [11C]
carbon dioxide (Cyclone 18/9 cyclotron, IBA, Louvain-
la-Neuve, Belgium) on the basis of already published con-
ditions using a commercially available TRACERLab™
FX-C synthesizer (GEMS, Buc, France) [19].
Ready-to-inject, >99% radiochemically pure [18F]DPA-714
(N,N-diethyl-2-(2-(4-(2-[18F]fluoroethoxy)phenyl)-5,7-dime-
thylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide) was prepared
from cyclotron-produced [18F]fluoride (Cyclone 18/9 cyclo-
tron, IBA, Louvain-la-Neuve, Belgium) on the basis of already
published standard conditions [20] using a commercially avail-
able TRACERLab™ FX-FN synthesizer (GEMS, Buc,
France) [21], a process which was formerly performed on a
Zymate XP robotic system (Zymark, Hopkinton, MA, USA)
[22]. Radiolabelling of DPA-714 with 18F (half-life 109.8 min)
uses a tosyloxy-for-fluorine nucleophilic aliphatic substitution
(one-step process) and its preparation includes the following
five stages: (1) dilution of the no-carrier-added, dried
(activated) K[18F]F-Kryptofix® 222 complex (prepared
from [18F]fluoride, potassium carbonate and Kryptofix®
222) with 700 μl of dimethyl sulphoxide (DMSO) containing
3.5–4.5 mg of the tosyloxy precursor for labelling
(N,N-diethyl-2-(2-(4-(2-toluenesulfonyloxyethoxy)phenyl)-
5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide); (2)
heating the reaction mixture at 160°C for 5 min; (3) dilution
of the reaction mixture with the HPLC mobile phase and pre-
purification on a Sep-Pak® Alumina N™ cartridge; (4) HPLC
purification on a semi-preparative Waters XTerra™ C18 col-
umn [eluent 0.1 M aq. ammonium acetate (pH 10)/acetonitrile:
60/40 (v:v)]; and (5) Sep-Pak® Plus C18 cartridge-based
removal of the HPLC solvents. [18F]DPA-714, as an ethanolic
(15%) physiological saline (aq. 0.9% NaCl) solution (6.7- to
8.5-GBq batches, 10-ml volume), is routinely obtained within
50–55 min starting from 35 GBq of [18F]fluoride (19–24%
non-decay-corrected overall isolated yields) with specific
radioactivities ranging from 74 to 222 GBq/μmol. Quality
controls were performed on an aliquot of the ready-to-inject
[18F]DPA-714 preparation, in compliance with our in-house
quality control/assurance specifications
Solutions of (R,S)-PK11195 for i.v. injection were prepared
by dissolving 2–3 mg of the compound in DMSO (0.2 ml),
followed by dilution with PEG 400 (1 ml) and finally physio-
logical saline (aq. 0.9% NaCl, 2 ml). Similarly, solutions of
unlabelled DPA-714 for i.v. injection were prepared by dis-
solving 2–3 mg of the compound in DMSO (0.2 ml), followed
by dilution with PEG 400 (0.4 ml) and finally physiological
saline (aq. 0.9% NaCl, 1.2 ml). Both solutions were systemat-
ically freshly prepared on the day of the in vivo experiment,
stored at room temperature and used within 2 h.
Cell cultures
The rat 9L and C6 as well as the mouse GL261 glioma cell
lines were maintained in culture using Dulbecco’s modified
Eagle’s medium (DMEM, Life Technologies®, Karlsruhe,
Germany) containing 10% fetal bovine serum (FBS, Roche
Diagnostics®, Mannheim, Germany) and 1% antibiotics
(penicillin/streptomycin, Life Technologies®) and were
grown at 37°C in a humidified atmosphere of 5% CO2.
Animal model
All experiments were performed under an animal use and
care protocol approved by the Animal Ethics Committee,
and they were conducted in accordance with the European
Union regulations on animal research.
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9L rat glioma cells were stereotactically implanted in the
striatum of Fischer (n05), Wistar (n08) and Sprague Dawley
(n05) rats. Intracranial 9L tumours were established by injec-
tion of 2×105 9L cells (in 1 μl DMEM) into the right striatum
using a Hamilton syringe in a stereotactic apparatus (Stoelting).
Cells were slowly infused (200 nl/min) and the syringe was left
in place after injection for an additional 5 min before it was
retracted slowly. The coordinates used were 4 mm lateral to the
bregma and 5 mm in depth to the dural surface.
Magnetic resonance imaging (MRI)
All scans were performed on a horizontal bore, 7 T Pharma-
Scan Bruker imaging system equipped with gradients with a
maximum strength of 760 mT/m. A 3.6-cm ID quadrature
radiofrequency (RF) coil was used for transmission and
reception. Scout scans and anatomical images were acquired
to localize the tumours. We ensured good B0 homogeneity
through automatic iterative FASTMAP methods (ParaVision
5.1). T2-weighted images were acquired using a fast spin-
echo sequence [effective echo time (TEeff)060 ms, acceler-
ation factor 8, repetition time (TR)03,000 ms, field of view
(FOV) 2.56×2.56 cm2, matrix size 128×128, slice thickness
0.3 mm, 8 averages, acquisition time 3 min 24 s]. During the
MRI acquisition the animals were anaesthetized with 2%
isoflurane in air administered using a nose cone. We mon-
itored the respiration rate and maintained the body temper-
ature at 37°C.
PET scan and data acquisition
To monitor tumour growth by PET in vivo, L-[S-methyl-11C]
methionine ([11C]MET) as well as [18F]DPA-714 dynamic
PET scans were acquired 11–14 days post-inoculation. The
injected doses were 2.70±0.66 mCi (mean±SD) and 1.44±
0.34 mCi (mean±SD) for [11C]MET and [18F]DPA-714,
respectively. Imaging was performed on a Siemens Focus
220 microPET scanner. [11C]MET PET was performed in
selected animals. Animals were anaesthetized with isoflurane
(induction: 4%, maintenance: 2–2.5%) in a mixture of 100%
O2. During PET imaging, the rat’s head was fixed in a home-
made stereotactic frame compatible with PET acquisition.
Rats were kept normothermic using a heating blanket
(Homeothermic Blanket Control Unit, Harvard Apparatus
Edenbridge, Kent, UK). Radiolabelled compounds and unla-
belled ligands [PK11195 (n1 mg/kg05, n5 mg/kg04); DPA-714
(n1 mg/kg07, n5 mg/kg04)] were injected into the caudal vein
through a 24-gauge catheter. PET data were acquired during
60 min for [11C]MET and 70 min for [18F]DPA-714, follow-
ing radiotracer injection. For in vivo displacement studies one
PET scan of 70 min was performed where radiolabelled com-
pounds were injected at the start of the PET acquisition and
unlabelled compounds were injected at 1.0 and 5.0 mg/kg
30 min after injection of the radiotracers. The acquisition
protocol used the following parameters: the time coincidence
windowwas set to 6 ns and the levels of energy discrimination
were set to 350 and 750 keV. The data files acquired in list
mode were histogrammed into 3-D sinograms with a maxi-
mum ring difference of 47 and span of 3. For [11C]MET, the
list-mode data of the emission scans were sorted into 18
frames. For [18F]DPA-714, the list-mode data were sorted into
24 dynamic frames or into 29 dynamic frames for displace-
ment studies in order to better define the displacement time
course. Two different methods were used to obtain the atten-
uation correction factors: (1) for [11C]MET experiments a
transmission scan was performed prior to radiotracer injection
using an external 68Ge point source and (2) for [18F]DPA-714
experiments segmentation of the emission map was used to
calculate the attenuation map as reported previously [18, 23].
Finally, the emission sinograms (i.e. each frame) were nor-
malized, corrected for scatter, attenuation and radioactivity
decay and reconstructed using Fourier rebinning (FORE)
and 2-D ordered subset expectation maximization (OSEM)
(16 subsets and 4 iterations).
Image analysis and modelling
PET image analysis was performed using VINCI, a fast
graphical image analysis package [24] with image coregistra-
tion tools. The Anatomist BrainVISA software package
(http://www.brainvisa.info) was also used for data evaluation.
PET images were coregistered to the corresponding MRI. For
quantitative analysis a volume of interest (VOI) analysis was
performed on kinetic as well as summed image data sets. A
VOI was manually delineated on the tumour, and as reference
region a mirror VOI was copied and symmetrically pasted into
the contralateral hemisphere. For this, we first automatically
reoriented the summed PET image so as to realign the inter-
hemispheric plane with the centre plane of the image grid.
This procedure was equivalent to computing the transforma-
tion defining an appropriate plane to split the brain into two
roughly symmetric parts and then realigning this plane—
defined as the mid-sagittal plane—with the centre of the
image lattice. We then applied this previously computed
transformation to the VOI (outlined on non-reoriented PET)
and flipped the resampled VOI with respect to the centre plane
of the image grid (i.e. the plane best superposing the two
hemispheres of the brain by reflective symmetry). A visual
inspection of the VOI transformation assured VOI placement
in the contralateral brain hemisphere. In order to investigate
another reference region we also manually defined a VOI in
the cerebellum, which is frequently used as a reference region
in clinical [11C]PK11195 or [123I]iodo-PK11195 studies of
Alzheimer’s disease [25–27].
For PET data modelling, the simplified reference tissue
model (SRTM) [28] from the PMOD software package
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(version 2.5, PMOD Technologies Ltd., Zurich, Switzerland)
was used to assess the BP in the target VOI. This model relies
on a two-tissue reversible compartment for the target region
(here tumour VOI) and a single-tissue compartment for the
reference volume (here contralateral or cerebellum). Three
parameters were estimated for each kinetic: R1 (K1/K’1),
which represents the ratio of tracer delivery; k2, which is the
clearance from the target tissue back to the vascular compart-
ment; and BPND (k3/k4), which is the binding potential of the
tracer to the tissue and refers to ratio of specifically bound
radioligand to that of non-displaceable radioligand in tissue at
equilibrium [29]. In order to evaluate the impact of R1 on the
BPND we recalculated the generated kinetic modelling files in
the kinetic modelling tool of PMOD and manually set R1
values equal to 1 with unchanged k2 and BPND values
before recalculation of simulated curve fits. This method
was previously described for the TSPO radioligand [11C]
DPA-713 [30] to evaluate the impact of flow effects on
the measured BPND.
Western blot
Proteins were extracted from 9L, C6 and GL261 cultured
cell suspensions. Cells were lysed in buffer containing
50 mM Tris-HCl pH 7.5, 1% (v/v) NP40, 0.5% (w/v)
sodium deoxycholate, 50 mM NaPPi, 100 mM NaF, 5 mM
Na3VO4, 150 mM NaCl and protease inhibitor mix (Roche
Diagnostics GmbH, Mannheim, Germany). The amount of
protein present in each sample was quantified using a BCA
Protein Assay (Pierce, Rockford, IL, USA). Equal amounts
(10 μg) of denatured (95°C, 5 min) protein were separated
using sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) and blotted to polyvinylidene difluor-
ide (PVDF) membrane (Amersham Pharmacia Biotech,
Freiburg, Germany) in standard Tris-glycine transfer buffer.
After blocking of non-specific binding sites with 3% bovine
serum albumin (BSA) or 3% non-fat dry milk in 0.2%
phosphate-buffered saline (PBS)-Tween 20 (PBST) for 2 h
at room temperature the membrane was washed three times
with PBST. Incubation with the primary antibodies diluted
in PBST with 3% of BSA for the anti-TSPO antibody and
3% non-fat dry milk for the anti-β-actin antibody, respec-
tively (1/10,000 dilution of the anti-rat TSPO antibody
NP155 [31] generously provided by Dr. M. Higuchi, NIRS,
Japan, and 1/5,000 dilution of the anti-β-actin antibody
purchased from Sigma Aldrich), was performed overnight
at 4°C. After three wash steps, the membrane was incubated
with the appropriate secondary antibody (1/2,000 dilution)
in 1% of BSA or 1% non-fat dry milk in PBST for 1 h at
room temperature. After three 10-min wash sessions, the
membrane was then developed using an Amersham ECL Plus
Western Blotting System (GE Healthcare Life Sciences) onto
films. Western blots were normalized using the anti-β-actin
antibody.
Immunohistochemistry
For immunohistochemical labelling, brains of tumour-bearing
animals were frozen in isopentane and stored at −80°C.
Coronal brain sections of 5 μm thickness were prepared
on a cryostat and were treated as reported previously
[32]. Sections were incubated with primary antibodies
[rabbit anti-rat TSPO antibody NP155, 1:1,000 gener-
ously provided by Dr. M. Higuchi, NIRS, Japan, mouse
anti-rat CD11b, 1:300 (Serotec, Raleigh, NC, USA) and
chicken anti-rat glial fibrillary acidic protein (GFAP),
1:500 (Abcam)] at room temperature for 1 h. The ex-
cess antibody was removed by three consecutive wash
cycles with PBS. Then the appropriate secondary anti-
bodies coupled with fluorophores (goat anti-rabbit IgG
with Alexa Fluor 488 nm for the rat anti-TSPO anti-
body NP155, goat anti-mouse IgG with Alexa Fluor
594 nm for CD11b and goat anti-chicken IgG with
Alexa Fluor 647 nm for the anti-GFAP antibody) or
horseradish peroxidase (HRP) (goat anti-rabbit IgG for
the rat anti-TSPO antibody NP155) were added to each
slide for 30 min, following by another three washes
with PBS. On each slide, one small tissue section incu-
bated with the secondary antibody without the primary
antibody served as controls. Finally, the ProLong® gold
antifade reagent with 4′-6′-diamidino-2-phenylindole
(DAPI) (purchased from Invitrogen) was added to stain
the cell nuclei and mount the slide. Fluorescent micros-
copy was performed using a Zeiss AxioCam with a
HXP 120 module (Carl Zeiss S.A.S.).
Statistical analysis
Differences between the three rat strains in the tumour
volume versus contralateral brain hemisphere were analysed
using one-way analysis of variance, and Bonferroni’s mul-
tiple comparison tests were used for post hoc analysis
(GraphPad Prism, GraphPad Software Inc.).
Results
TSPO expression in glioma cell lines and in 9L glioma
Western blot results demonstrated a level of TSPO ex-
pression in 9L cells similar to that in rat C6 glioma
cells (Fig. 1a), which served as positive controls [33,
34]. In contrast, murine glioma GL261 cells did not
show significant expression of TSPO. Histology and
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immunohistochemistry of intracranially growing 9L rat
gliomas demonstrated clear tumour growth [haematoxy-
lin and eosin (H&E) staining; Fig. 1b] and strong TSPO
expression (anti-TSPO staining; Fig. 1c).
In vivo imaging of 9L glioma
To monitor tumour growth in vivo, T2-weighted MRI and
[11C]MET PET were performed prior to [18F]DPA-714 PET
imaging. 9L glioma cell inoculation resulted in tumour
growth as evidenced by T2-weighted MRI and [11C]MET
PET (Fig. 2a). [18F]DPA-714 PET images were coregistered
to the corresponding MRI and demonstrated significant
[18F]DPA-714 accumulation at the site of tumour implanta-
tion (Fig. 2a). MRI and [18F]DPA-714 PET imaging of
sham-operated animals did not demonstrate any significant
[18F]DPA-714 accumulation at the site of the needle tract
(Fig. 2b).
Quantitative analysis of [18F]DPA-714 uptake in 9L glioma
in vivo
9L cell implantation in (1) syngeneic Fischer rats, (2) allo-
geneic Wistar rats [35] and (3) Sprague Dawley rats resulted
in tumour growth in all strains. Although all three rat strains
manifested significant [18F]DPA-714 PET uptake in the
tumour as compared to the contralateral site or cerebellum,
time-activity curves (TACs) as well as calculation of %ID/cc
showed significant differences between tumour and contra-
lateral region or tumour and cerebellum in all strains (Fig. 3;
Fig. 1 a Expression levels of TSPO measured in protein extracts from
rat and murine glioma cell lines (9L, C6 and GL261). Western blots
were normalized using the anti-β-actin antibody. H&E staining (b) and
immunohistochemistry for TSPO (c) of coronal brain sections illustrat-
ing tumour growth and high level of TSPO expression in a 9L glioma
Fig. 2 T2-weighted MRI and PET imaging of animals bearing i.c.
9L rat glioma (a) and sham-operated animals (b). T2-weighted
MRI and summed [11C]MET PET images (0–60 min) illustrate
tumour growth; summed [18F]DPA-714 PET images (0–70 min)
demonstrate significant tracer uptake in tumour as compared to
the contralateral site (a). [18F]DPA-714 PET image of a sham-
operated animal shows no important [18F]DPA-714 uptake at the
site of the needle tract
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p<0.001). Mean [18F]DPA-714 uptake in the tumour was
0.49±0.05%ID/cc, 0.37±0.10%ID/cc and 0.28±0.08%ID/
cc in Fischer, Wistar and Sprague Dawley rats, respectively
(Fig. 3, box plot). Calculation of control VOIs in the
contralateral hemisphere resulted in [18F]DPA-714 uptake
values of 0.15±0.02%ID/cc (Fischer), 0.13±0.04%ID/cc
(Wistar) and 0.10±0.01%ID/cc (Sprague Dawley). Similar
results were obtained using the cerebellum as control region
(0.16±0.02%ID/cc (Fischer), 0.11±0.03%ID/cc (Wistar)
and 0.08±0.01%ID/cc (Sprague Dawley). Representative
[18F]DPA-714 TACs of tumour and corresponding model
fits (simplified reference tissue model) for individuals of the
three rat strains are illustrated in Fig. 4. TACs of standard-
ized uptake values (SUVs, %ID/cc per kg) demonstrate
significantly higher uptake of [18F]DPA-714 in the tumour
versus contralateral region or cerebellum [p<0.001 in
Fischer and Wistar, p<0.01 in Sprague Dawley rats (data
not shown)]. TACs of the two reference regions appear
similar although differences exist within the first 10 min
of the PET scan. Mean uptake values±SD in tumour were
Fig. 3 TACs of a VOI placed on the tumour and the contralateral
hemisphere for [18F]DPA-714 in Fischer (n05),Wistar (n08) and Sprague
Dawley (n05) rats. Box plot of corresponding VOI analysis shows
significant differences in [18F]DPA-714 uptake in tumour vs control
(***p<0.001) or cerebellum (###p<0.001) in all strains. VOI analysis
was performed on summed images over the last 30 min of the PET scan
Fig. 4 Representative [18F]DPA-714 TACs and model fits (SRTM) for
tumour of a Fischer (black square), a Wistar (open circle) and a
Sprague Dawley rat (triangle)
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2.18±0.34, 1.16±0.32 and 0.67±0.23 in Fischer, Wistar and
Sprague Dawley rats, respectively. SUVs of control regions
did not differ significantly between the Fischer (0.66±0.08
contralateral versus 0.68±0.07 cerebellum), Wistar (0.41±
0.15 contralateral versus 0.33±0.08 cerebellum) or Sprague
Dawley strains (0.23±0.03 contralateral versus 0.19±0.01
cerebellum).
Kinetic modelling
Kinetic modelling of the PET data using the SRTM [28]
estimated the BPND (binding potential), R1 (ratio of tracer
delivery) and k2 (efflux constant) values. A VOI placed in
the contralateral mirror region to the tumour and a VOI
placed in the cerebellum were compared as reference
regions in SRTM. The BPND for [
18F]DPA-714 using the
contralateral VOI as reference region was similar in the
three different rat models (mean values±SD were 2.17±
0.53, 2.05±0.96 and 2.03±0.48 in Fischer, Wistar and
Sprague Dawley rats, respectively) (Table 1). Corresponding
R1 values for [
18F]DPA-714were close to 1 (1.24±0.19, 1.33±
0.17 and 1.42±0.31 for Fischer, Wistar and Sprague Dawley
rats) and did not show significant differences between strains.
No differences were found either for k2, the clearance from the
target tissue back to the vascular compartment: 0.15±0.07,
0.16±0.06 and 0.12±0.07 min−1, for Fischer, Wistar and
Sprague Dawley rats, respectively. Since R1 values were
higher than 1, we recalculated simulated TACs after imposing
an R1 value of 1, in order to investigate the influence on the
BPND. With R101 BPND values for the three rat strains were
not significantly different from those obtained using the non-
imposed R1 (Fischer: 2.17±0.53 vs 2.00±0.52, p>0.05;
Wistar 2.05±0.96 vs 1.75±0.52, p>0.05; and Sprague
Dawley 2.03±0.48 vs 1.70±0.44, p>0.05). Using the cerebel-
lum as reference region, no significant differences were found
when comparing R1, k2 or BPND values between the different
rat strains. Furthermore, comparing the values calculated with
the cerebellum as reference region, BPND and k2 did not differ
significantly from those obtained with the contralateral region
as reference region. However, calculated R1 values in Fischer
rats using cerebellum as reference region were significantly
smaller compared to those obtained with contralateral VOI as
reference region (p<0.05). The same differences were found
for R1 values in Wistar and Sprague Dawley rats when using
the cerebellum versus the contralateral site as reference region
(both p<0.001).
In vivo displacement studies
In vivo displacement studies by administration of 1 and
5 mg/kg of either unlabelled DPA-714 or the reference com-
pound PK11195, 30 min after tracer injection, resulted in a
significant reduction in the tumour radioactivity concentra-
tions (p values for displacement with 1 or 5 mg/kg of DPA-
714 were p<0.01 and p<0.001, respectively; and for displace-
ment with 1 or 5 mg/kg of PK11195, p values were p>0.05
and p<0.05, respectively; Fig. 5). Injection of 1 mg/kg of
unlabelled compounds reduced the radiotracer uptake to 62
and 74% of its pre-displacement value, respectively (Table 2).
Accordingly, administration of higher amounts of unlabelled
DPA-714 or PK11195 (5 mg/kg) induced stronger displace-
ments resulting in 15 and 45% of radiotracer uptake in the
tumour compared to pre-displacement values (Table 2). PET
images and mean TACs (Fig. 6) showed a rapid and nearly
complete displacement of [18F]DPA-714 after injection of
DPA-714, and radioactivity concentration in the tumour area
decreased to a level similar to that measured in the contralat-
eral brain area. Displacement with an excess of PK11195 also
demonstrated a significant level of displaceable binding, al-
though lower than with DPA-714.
Table 1 R1, k2 and BPND values obtained from [
18F]DPA-714 PET data in Fischer, Wistar and Sprague Dawley rats using contralateral site or
cerebellum as reference region
Fischer Wistar Sprague Dawley
Number of rats n05 n08 n05
R1 (reference region contralateral) 1.24±0.19 1.39±0.27 1.42±0.31
R1 (reference region cerebellum) 0.88±0.12* 0.91±0.16*** 0.82±0.24***
k2 (reference region contralateral) 0.15±0.07 0.16±0.06 0.12±0.07
k2 (reference region cerebellum) 0.14±0.09 0.09±0.03 0.11±0.03
BPND (reference region contralateral) 2.17±0.53 2.05±0.96 2.03±0.48
BPND (reference region cerebellum) 2.03±0.53 2.55±0.79 2.24±1.11
Results are expressed as mean values±SD. No significant differences were found when comparing R1, k2 or BPND values between the different rat
strains; however, R1 values from Fischer, Wistar and Sprague Dawley rats were significantly different depending on the reference region selected
for calculations in SRTM. The calculated R1 value in Fischer rats using cerebellum as reference region was significantly smaller as compared to
contralateral VOI as reference region (*p<0.05). The same is true for R1values in Wistar and Sprague Dawley rats comparing cerebellum and
contralateral site as reference region (both ***p<0.001). No significant differences were found for k2 or BPND comparing the two reference regions
R1 ratio of tracer delivery, k2 efflux constant, BPND binding potential. Results are expressed as mean values±SD
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Immunohistochemistry
In order to analyse TSPO expression at the cellular level we
performed immunofluorescence labelling of TSPO in the rat
9L gliomas. Tumours grown intracerebrally showed com-
plex tissue composition, comprising cancerous cells as well
as cells of the tumour microenvironment (TME) such as
endothelial cells, vessels and cells of the immune system
such as glioma-infiltrating microglia/macrophages [36].
Since it is known that TSPO expression is dramatically
increased upon activation of glial cells, we performed triple
immunostaining for TSPO, CD11b and GFAP to investigate
separately TSPO expression in activated glioma-infiltrating
microglia/macrophages or astrocytes and in 9L glioma cells.
Previous data have suggested that systemic macrophages are
the predominant inflammatory cells infiltrating gliomas [37,
38]. However, since the origin of tumour-associated micro-
glia/macrophages has not yet been fully determined [39]
labelling with CD11b reflects both resident microglia as
well as glioma-infiltrating macrophages. A panoramic view
of TSPO immunofluorescence demonstrates that TSPO ex-
pression was mostly restricted within the tumour (Fig. 7a),
confirming the PET results. CD11b immunolabelling revealed
the presence of microglial/macrophage cells within the tu-
mour, whereas GFAP staining did not show the presence of
astrocytes in the tumour. Higher magnification showed a high
level of TSPO expression in activated microglial/macrophage
cells. Although the bulk expression of TSPO originated from
glioma cells, these results clearly demonstrate that the TSPO
signal derived in vivo originates from both cancerous and
immune cells (Fig. 7b).
Discussion
The present study evaluated the potential use of the TSPO
radioligand [18F]DPA-714 as a PET imaging marker for
non-invasive imaging of intracranial rat glioma models in
vivo. [18F]DPA-714 PET imaging of 9L gliomas grown in
three different rat strains (Fischer, Wistar and Sprague
Dawley rats) demonstrated significant [18F]DPA-714 PET
uptake at the site of tumour implantation as compared to the
contralateral brain hemisphere or cerebellum, and in vivo
displacement studies with unlabelled DPA-714 or PK11195
showed high specificity of [18F]DPA-714 for TSPO. Finally,
immunohistochemistry of brain/tumour sections confirmed
high TSPO expression within the glioma and demonstrated
the presence of TSPO-positive glioma as well as TSPO-
positive microglial cells (Fig. 7).
The gold standard imaging method for the diagnosis
of human gliomas is T1-weighted MRI with and without
gadolinium enhancement in conjunction with T2-weighted
MRI. These sequences provide information on the size and
localization of the tumour and additional information about
secondary phenomena such as disruption of the blood-brain
barrier, mass effect, perifocal oedema, haemorrhage, necrosis
and signs of increased intracranial pressure [40]. However, no
specific information about the biological or metabolic activity
of the tumour is provided by T1- or T2-weightedMRI. Recent
reviews point out the usefulness of combining advanced
Fig. 5 In vivo displacement of [18F]DPA-714 by injection of DPA-714
or PK11195 with 1 mg/kg (a) and 5 mg/kg (b), respectively. Graphs
illustrate %ID/cc values before versus after administration of the unla-
belled compound in tumour and control VOIs. Measurements for pre-
and post-displacement were compared at 27.5 and 47.5 min after
radiotracer injection, two time points with identical frames of PET
data acquisition. [18F]DPA-714 uptake decreased significantly in the
tumour VOI after displacement with DPA-714 at 1 mg/kg (**p<0.01)
and 5 mg/kg (***p<0.001) or with 5 mg/kg PK11195 (*p<0.05)




1 mg/kg 62.3±27.6 56.3±9.2 46.4±5.0
5 mg/kg 14.5±0.4 35.4±7.9 44.5±11.7
+ PK11195
1 mg/kg 74.0±24.3 51.3±5.9 49.0±5.2
5 mg/kg 44.8±13.0 46.6±11.9 44.6±8.7
Results are expressed as % of radiotracer uptake of pre-displacement
value
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imaging methods, in particular PET in conjunction with MRI,
to visualize additional molecular information and biological
changes of the tumour [41, 42]. Overexpression of TSPO has
been reported in a variety of cancer cell lines and human
tumours including glioma [8], and clinical studies using the
TSPO radioligand [11C]PK11195 imaged human glioma us-
ing PET [10, 17]. However, this radioligand has various
limitations, among others, the labelling with 11C (T1/2:
20.4 min) restricts its extensive clinical use [2]. In the last
few years many efforts have been undertaken in the develop-
ment of new TSPO radioligands. One of the [11C]PK11195
challengers that showed improved characteristics when com-
pared to the reference compound is the pyrazolo[1,5]pyrim-
idine [18F]DPA-714 [20]. In a rat model of neuroinflammation,
[18F]DPA-714 was directly compared to [11C]PK11195 and
another pyrazolo[1,5]pyrimidine [11C]DPA-713 [18] and
demonstrated improved signal to noise ratio and increased BP
as compared to [11C]PK11195. Martín et al. used this TSPO
radioligand to characterize the time course of TSPO expression
in an animal model of focal cerebral ischaemia [32]. Other new
TSPO radioligands reported include the phenoxyarylaceta-
mides [11C]DAA1106, [11C]PBR28 or [18F]PBR06, which
have been claimed to perform better than [11C]PK11195 for
in vivo imaging of TSPO, based on higher binding affinity in an
animal model of neuroinflammation [43] and high levels of
specific binding in non-human primates and in human brain
[44, 45]. The new TSPO ligands may redraw attention to TSPO
PET imaging of gliomas, as suggested by a recent study of in
vivo imaging of [18F]PBR06 in a preclinical model of glioma
[33].
Here we demonstrate that 9L glioma cells as well as
intracranial 9L gliomas express TSPO at a high level. In
vivo PET imaging of [18F]DPA-714 in the 9L glioma model
resulted in high [18F]DPA-714 uptake in the tumour as
compared to the contralateral brain hemisphere. Comparison
with sham-operated animals shows that the PET signal was
not influenced by an uptake of [18F]DPA-714 due to a
neuroinflammatory reaction induced by the operation pro-
cedure itself (Fig. 2).
TACs for tumour VOIs demonstrate a slow washout of
[18F]DPA-714 as compared to control brain regions, as
previously reported in a rat model of focal cerebral ischae-
mia [32]. Slow washout may also be a characteristic of the
rat glioma model. Using [18F]PBR06 in a C6 glioma model
in Wistar rats, Buck et al. also demonstrated a slower wash-
out of this radioligand from the tumour tissue than from the
contralateral brain, thus facilitating a strong tumour to con-
tralateral brain contrast [33].
The 9L glioma originates from a tumour that arose in
Fischer rats [46]. However, 9L cells can also form tumours
in allogeneic Wistar [35] and Sprague Dawley rats [47].
Quantitative data analysis demonstrated that [18F]DPA-714
uptake was significantly enhanced in the tumour as com-
pared to the contralateral brain hemisphere or cerebellum in
Fig. 6 Summed [18F]DPA-714 PET images before (0–30 min) and after (40–70 min) in vivo displacement with 5 mg/kg DPA-714 (a) or PK11195
(b). TACs for [18F]DPA-714 in tumour and control VOI after injection of DPA-714 (c) or PK11195 (d)
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all of the three strains. Furthermore, differences in the ra-
dioactivity concentrations expressed in %ID/cc or SUVs in
the tumour were observed between the different rat strains
regardless of body weight. An explanation for the differ-
ences in the %ID/cc values in the tumour may result from
the tumour model itself. Since 9L cells are allogeneic to
Wistar or Sprague Dawley rats, the tumours may present
different stages of carcinogenesis and thus e.g. express
proteins at different levels, as previously shown for K
(ATP) and K(Ca) channels when 9L tumours were com-
pared in Wistar and Fischer rats [35]. Another factor that
may influence specific radiotracer binding is the contribu-
tion of the TME, in particular the presence of inflammatory
cells such as activated microglia, which may be different for
9L tumours in syngeneic or allogeneic rats. Inter-strain
differences in radiotracer plasma availability (due to excretion,
metabolism or binding to plasma proteins) or differences in
cerebral vascularization may also contribute to the differences
measured in tumour radioactivity concentration. Wistar rats
present a significantly greater number of proximal side
branches of the long proximal middle cerebral artery segment
than Fischer rats [48]. Since %ID/cc values represent a com-
bination of free, specifically and non-specifically bound radio-
ligand in a target region, we modelled PET data using the
SRTM [28]. It should be noted that one of the requirements of
SRTM is the use of a reference regionwithout specific binding
of the ligand. In order to normalize for inter-strain differences
we performed our calculations using SRTM, although there is
a small displaceable binding in both reference regions ana-
lysed in our study. Estimated R1, k2 and BPND values did not
show significant changes between the rat strains independent-
ly of the reference region chosen, suggesting that the inter-
strain differences are likely due to anatomical and/or radio-
tracer metabolism variations between strains. However, a
difference was found for R1 values, whether the contralateral
side or the cerebellum were taken as reference region (p<0.05
and p<0.001 for Fischer and Wistar or Sprague Dawley rats,
respectively, Table 1). This may be explained by the differ-
ences seen in particular for the first minutes of TACs, as R1
defined as the ratio of tracer delivery (K1/K1’) and K1 and K1’,
respectively, are mainly determined by the first minutes after
radiotracer injection.
As R1 values (K1/K1’) calculated with the contralateral
side as reference region were higher than 1 (1.24±0.19,
1.33±0.17 and 1.42±0.31 for Fischer, Wistar and
Sprague Dawley rats), indicating a facilitated entry of
the radioligand into the tumour as compared to the ref-
erence region, we examined whether increased [18F]DPA-
714 uptake into the tumour may have been due to dis-
ruption of the blood-brain barrier. However, imposing a
hypothetical R1 value of 1 did not significantly influence
the BPND values, indicating that [
18F]DPA-714 delivery
into the tumour has only a limited effect on the BPND.
Accordingly, in vivo displacement studies demonstrated
that [18F]DPA-714 uptake reflects specific TSPO binding.
Increasing amounts of unlabelled compound (DPA-714 or
PK11195) yielded an increased displacement of tumour
radioactivity concentrations. A dose of 5 mg/kg of unla-
belled DPA-714 displaced more than 85% of the in vivo
tumour uptake, whereas only 55% of the original tumour
radioactivity concentration was displaced after administra-
tion of 5 mg/kg unlabelled PK11195 (Fig. 5b, Table 2). This
difference in the displacement of the TSPO radioligand
using the corresponding unlabelled compound or unlabelled
PK11195 has previously been reported [32] and is likely due
to a higher level of specific versus non-specific binding of
DPA-714. It is most unlikely due to differences in affinities
since in an in vitro binding assay, James et al. showed that
affinities of DPA-714 and PK11195 for TSPO are comparable
Fig. 7 Immunohistochemistry of TSPO (green), CD11b (red) and
GFAP (white) on whole coronal brain sections of animals bearing i.c.
9L glioma (a) illustrates strong TSPO expression and the presence of
CD11b-positive microglial/macrophage cells in the tumour. In contrast,
GFAP staining did not reveal the presence of astrocytes within the
glioma. Triple labelling at higher magnification (b) shows a number of
CD11b-positive microglia/macrophages present in the tumour express-
ing a high level of TSPO. Nuclear counterstaining was performed
using DAPI (blue)
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[affinity of DPA-714 (Ki07.0±0.4 nM); affinity of PK11195
(Ki09.4±0.5 nM)] [20]. The differences in displacement
efficiency may be explained by the fact that PK11195 is in a
racemic form while DPA-714 is not. It is known that only the
R-enantiomer of PK11195 is pharmacologically active, thus
the displacing dose of PK11195 is half that of DPA-714.
Recently, PET studies using [11C]PBR28 demonstrated
differences in affinity for TSPO in humans [49–51]. In a
PET study with healthy human subjects, Fujita et al.
reported the existence of non-binders for [11C]PBR28,
whereas no such phenomenon has been described for [11C]
PK11195 [49]. At a later date Owen et al. reported the
presence of three different binding patterns with PBR28
(high-affinity binding, low-affinity binding and mixed-
affinity binding), whereas no difference in affinity of
PK11195 for TSPO was found in their study [51]. Further-
more, a recent study by the same group demonstrated that
other TSPO ligands, currently used in clinical studies, can
distinguish between these three binding patterns, although
the differences in affinity do vary depending on the radio-
ligand [52]. Strong differences were found for the phenox-
yphenyl acetamides PBR28 and PBR06 (Ki ratio LAB to
HAB: 55 and 17, respectively), whereas others like the
phenylimidazopyridine PBR111, the phenylpyrazolopyrimi-
dine DPA-713 or the phenoxyphenyl acetamide DAA1106
demonstrated only smaller differences in affinity (four- to
fivefold). Although it is likely that [18F]DPA-714, which is
an 18F-labelled derivative of DPA-713, will demonstrate a
similar low difference in affinity ratio (low- versus high-
affinity binding), this remains to be demonstrated.
In contrast to [11C]PBR28, PET studies with [18F]PBR06,
[18F]PBR111, [11C]DPA-713 and [11F]DAA1106 did not re-
port the phenomenon of low-affinity binding, probably due to
an affinity for the respective PET radioligand sufficient to
obtain a measurable PET signal [52]. At present the impact
of these differences in binding affinity on the interpretation of
the PET signal remains to be fully elucidated although it may
be expected that low-affinity binding sites should lead to an
underestimation of TSPO.
Gliomas are not exclusively composed of cancer cells but
also of cells of the TME [36]. In particular, microglia/
macrophages which can make up to 30% of the brain tu-
mour mass [39] and astrocytes which are found in the
proximity of glioma cells [53]. Increase in TSPO expression
is a hallmark of glial cell activation upon neuroinflammation
often associated with neoplastic processes. Thus, we tested
whether activated microglia/macrophages and astrocytes
contributed to the PET signal obtained in the glioma model
using triple immunolabelling of brain/tumour sections.
CD11b-positive microglia/macrophages were present within
the glioma and demonstrated TSPO expression. In contrast,
astrocytes were not found within the tumour and, thus, their
contribution to the observed TSPO signal may be regarded
as limited. Although the majority of the TSPO signal within
the tumour is provided by the glioma cells, activated micro-
glia/macrophages contribute to the TSPO signal and thus to
[18F]DPA-714 uptake in the tumour. In their in vivo imaging
study using [18F]PBR06 in a rat glioma model, Buck et al.
also demonstrated significantly higher TSPO immunostain-
ing in the glioma as compared to normal brain tissue, and
tumour to normal brain ratios were similar to TSPO protein
levels in tumour tissue as compared to normal brain tissue
[33]. However, no immunohistochemistry data about other
cells possibly contributing to the PET signal were provided.
The finding that microglia/macrophages account for the TSPO
signal may be of limited importance for diagnostic purposes
but may have significant implications when this radioligand is
employed for assessment of treatment response to i.e. radio-
therapy or combined radio- and chemotherapy.
Conclusion
This study demonstrates the feasibility of using PET imaging
with the TSPO radioligand [18F]DPA-714 to characterize 9L
glioma in vivo in different rat models. [18F]DPA-714 holds
potential for imaging gliomas in patients if future clinical
studies confirm the positive preclinical data reported here.
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